{"id":"copper-cu-64-psma-i-t","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation-related toxicity"},{"rate":null,"effect":"Hematologic effects"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297339","moleculeType":"Protein","molecularWeight":"1497.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This radiopharmaceutical uses copper-64, a positron-emitting isotope, conjugated to a PSMA-targeting ligand to enable both PET imaging and therapeutic delivery in PSMA-expressing tumors. The agent localizes to prostate cancer cells and other PSMA-positive malignancies, allowing for visualization and potential therapeutic irradiation. Cu-64's dual imaging and therapeutic capability (theranostic approach) enables both diagnostic assessment and treatment planning.","oneSentence":"Copper Cu 64 PSMA I&T is a radioactive diagnostic and therapeutic agent that binds to prostate-specific membrane antigen (PSMA) on cancer cells for imaging and treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:23.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (imaging and therapeutic indication)"},{"name":"PSMA-positive metastatic castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT06235099","phase":"PHASE3","title":"Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer","status":"COMPLETED","sponsor":"Curium US LLC","startDate":"2024-04-01","conditions":"Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate","enrollment":235},{"nctId":"NCT06235151","phase":"PHASE3","title":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","status":"RECRUITING","sponsor":"Curium US LLC","startDate":"2024-04-01","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":439},{"nctId":"NCT05653856","phase":"PHASE2","title":"Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer","status":"COMPLETED","sponsor":"Curium US LLC","startDate":"2022-12-05","conditions":"Metastasis From Malignant Tumor of Prostate (Disorder)","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Copper Cu 64 PSMA I&T","genericName":"Copper Cu 64 PSMA I&T","companyName":"Curium US LLC","companyId":"curium-us-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Copper Cu 64 PSMA I&T is a radioactive diagnostic and therapeutic agent that binds to prostate-specific membrane antigen (PSMA) on cancer cells for imaging and treatment. Used for Prostate cancer (imaging and therapeutic indication), PSMA-positive metastatic castration-resistant prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}